Avenue Therapeutics Stock Quote ATXI - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

2.70

Bid

2.51

Ask

3.50

Volume

0.00 Day's Range 0.00

2.25 52 Week Range 60.0075

Market Cap

3.865M

Previous Close

2.70

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

47,586

Shares Outstanding

1,431,356

Dividend Yield

PE Ratio

-0.37

Earnings Per Share (EPS)

-7.25

Revenue

Net Profit

-10.38M

Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain. Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.avenuetx.com

Headquarters

Dover, Delaware, USA

Founded

Avenue Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXI. The last closing price for Avenue Therapeutics was $2.70. Over the last year, Avenue Therapeutics shares have traded in a share price range of $ 2.25 to $ 60.0075.

Avenue Therapeutics currently has 1,431,356 shares outstanding. The market capitalization of Avenue Therapeutics is $3.86 million. Avenue Therapeutics has a price to earnings ratio (PE ratio) of -0.37.

Avenue Therapeutics to Participate in Upcoming Investor Conferences

MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and...

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

- Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 – - Raised $4.4 million in gross...

Form S-8 - Securities to be offered to employees in employee benefit plans

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Form 8-K - Current report

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.21	-7.21649484536	2.91	3.03	2.58	14635	2.76541189	CS
4	-0.17	-5.92334494774	2.87	3.54	2.47	22116	2.82406337	CS
12	-0.91	-25.2077562327	3.61	3.9313	2.25	47586	2.99110845	CS
26	-9.75	-78.313253012	12.45	12.75	2.25	388397	8.62996179	CS
52	-54.3	-95.2631578947	57	60.0075	2.25	2006060	17.31690334	CS
156	-1819.8	-99.8518518519	1822.5	2081.25	2.25	1801017	347.15343868	CS
260	-6781.05	-99.960199005	6783.75	14130	2.25	1143891	715.50113967	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ZEOZeo Energy Corporation	$ 4.15 (264.04%)	2.74M
XCURExicure Inc	$ 6.55 (186.03%)	2.89M
TBIOTelesis Bio Inc	$ 2.85 (109.56%)	3.31M
VEROVenus Concept Inc	$ 0.8336 (65.89%)	2.95M
VMARVision Marine Technologies Inc	$ 0.9775 (62.11%)	2.71M
BNRBurning Rock Biotech Ltd	$ 1.51 (-56.66%)	1
PGNYProgyny Inc	$ 18.51 (-24.26%)	28.54k
VEEAVeea Inc	$ 10.18 (-16.90%)	35.14k
SBCSBC Medical Group Holdings Incorporated	$ 6.50 (-15.14%)	15.66k
WBUYWeBuy Global Ltd	$ 0.1575 (-14.54%)	501.8k
FRGTFreight Technologies Inc	$ 0.1751 (41.32%)	23.08M
MAXNMaxeon Solar Technologies Ltd	$ 0.1154 (26.95%)	9.54M
TBIOTelesis Bio Inc	$ 2.85 (109.56%)	3.31M
VEROVenus Concept Inc	$ 0.8336 (65.89%)	2.95M
XCURExicure Inc	$ 6.55 (186.03%)	2.89M